Summary

There are few data regarding the efficacy and safety of simeprevir + sofosbuvir in patients with decompensated cirrhosis. Data from this study comparing this drug combination in patients with Child-Pugh B/C cirrhosis with patients who received older treatment regimens suggest that recently approved all-oral therapies offer patients with decompensated cirrhosis a safer and more effective therapy than historical peginterferon-based therapies.